DE69831741D1 - Modifizierte adenovirale fiber und sie enthaltende adenoviren - Google Patents

Modifizierte adenovirale fiber und sie enthaltende adenoviren

Info

Publication number
DE69831741D1
DE69831741D1 DE69831741T DE69831741T DE69831741D1 DE 69831741 D1 DE69831741 D1 DE 69831741D1 DE 69831741 T DE69831741 T DE 69831741T DE 69831741 T DE69831741 T DE 69831741T DE 69831741 D1 DE69831741 D1 DE 69831741D1
Authority
DE
Germany
Prior art keywords
adenovirus
adenovers
residues
modified adenoviral
fiber
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69831741T
Other languages
English (en)
Other versions
DE69831741T2 (de
Inventor
Valerie Legrand
Majid Mehtali
Pierre Boulanger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9703987A external-priority patent/FR2761688A1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Transgene SA filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of DE69831741D1 publication Critical patent/DE69831741D1/de
Publication of DE69831741T2 publication Critical patent/DE69831741T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Processing Of Solid Wastes (AREA)
DE69831741T 1997-04-02 1998-04-02 Modifizierte adenovirale fiber und sie enthaltende adenoviren Expired - Fee Related DE69831741T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9703987A FR2761688A1 (fr) 1997-04-02 1997-04-02 Fibre adenovirale modifiee et adenovirus cibles
FR9703987 1997-04-02
FR9704747 1997-04-17
FR9704747A FR2761689B1 (fr) 1997-04-02 1997-04-17 Fibre adenovirale modifiee et adenovirus cibles
PCT/FR1998/000668 WO1998044121A1 (fr) 1997-04-02 1998-04-02 Fibre adenovirale modifiee et adenovirus cibles

Publications (2)

Publication Number Publication Date
DE69831741D1 true DE69831741D1 (de) 2006-02-09
DE69831741T2 DE69831741T2 (de) 2006-07-06

Family

ID=26233432

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69831741T Expired - Fee Related DE69831741T2 (de) 1997-04-02 1998-04-02 Modifizierte adenovirale fiber und sie enthaltende adenoviren

Country Status (11)

Country Link
US (2) US6569677B1 (de)
EP (1) EP0991763B1 (de)
JP (1) JP2001522236A (de)
AT (1) ATE305513T1 (de)
AU (1) AU741728B2 (de)
CA (1) CA2285565A1 (de)
DE (1) DE69831741T2 (de)
DK (1) DK0991763T3 (de)
ES (1) ES2246533T3 (de)
FR (1) FR2761689B1 (de)
WO (1) WO1998044121A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
WO1999055365A1 (en) 1998-04-30 1999-11-04 Cornell Research Foundation, Inc. Adenoviral vectors with tandem fiber proteins
US6455314B1 (en) 1998-09-11 2002-09-24 Genvec, Inc. Alternatively targeted adenovirus
EP1020529B1 (de) * 1998-11-20 2005-06-01 Crucell Holland B.V. Genverabreichende Vektoren mit Gewebetropismus für glatte Muskelzellen und/oder Endothelzellen
IL133032A (en) * 1998-11-20 2007-06-03 Introgene Bv Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
JP2000279178A (ja) * 1999-02-24 2000-10-10 Japan Found Cancer Res ウイルスベクター
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
US7560527B1 (en) 1999-11-25 2009-07-14 Transgene S.A. Modified adenovirus fibre and uses
WO2001092547A2 (en) * 2000-05-31 2001-12-06 University Of Saskatchewan Modified bovine adenovirus having altered tropism
CA2410981A1 (en) * 2000-06-02 2001-12-06 Novartis Ag Adenovirus particles with mutagenized fiber proteins
CA2491805A1 (en) * 2002-07-10 2004-01-22 Transgene S.A. Modified adenoviral fiber with ablated binding to cellular receptors
WO2005027711A2 (en) * 2003-05-01 2005-03-31 University Of Washington Capsid-modified adenovirus vectors and methods of using the same
AU2004238979B2 (en) * 2003-05-14 2008-12-18 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Broadening adenovirus tropism
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
GB0313132D0 (en) * 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
WO2005030927A2 (en) * 2003-09-23 2005-04-07 Uab Research Foundation Methods and compositions for in vivo inflammation monitoring
ATE449105T1 (de) * 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
US20070010016A1 (en) * 2005-03-11 2007-01-11 Mccelland Alan Gene transfer with adenoviruses having modified fiber proteins
EP1893636A2 (de) * 2005-06-17 2008-03-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis-c-virus-nukleinsäureimpfstoff
WO2007094653A1 (en) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
EP1925664A1 (de) * 2006-11-15 2008-05-28 Scil proteins GmbH Künstliche Bindungsproteine auf Grundlage einer modifizierten alpha-Helix Region von Ubiquitin
US10131921B2 (en) * 2008-03-06 2018-11-20 Mayo Foundation For Medical Education And Research Single cycle replicating adenovirus vectors
AU2010332932B2 (en) 2009-12-14 2013-01-17 Navigo Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin
CA2837804C (en) 2011-06-15 2018-03-20 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
EP2971008B1 (de) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Onkolytische adenoviruszusammensetzungen
US10858405B2 (en) 2015-02-06 2020-12-08 Navigo Proteins Gmbh EGFR binding proteins
US10808042B2 (en) 2015-07-16 2020-10-20 Navigo Proteins Gmbh Immunoglobulin-binding proteins and their use in affinity purification
US10584152B2 (en) 2015-07-20 2020-03-10 Navigo Proteins Gmbh Binding proteins based on di-ubiquitin muteins and methods for generation
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2017191252A1 (en) 2016-05-04 2017-11-09 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
CA3030208A1 (en) 2016-08-11 2018-02-15 Navigo Proteins Gmbh Novel alkaline stable immunoglobulin binding proteins
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018035388A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
US20200405639A1 (en) 2017-04-14 2020-12-31 The Broad Institute, Inc. Novel delivery of large payloads
EP3706804B1 (de) 2017-11-07 2022-02-23 Navigo Proteins GmbH Fusionsproteine mit spezifität für ed-b und langer serumhalbwertszeit für diagnose oder behandlung von krebs
EP3710039A4 (de) 2017-11-13 2021-08-04 The Broad Institute, Inc. Verfahren und zusammensetzungen zur behandlung von krebs durch targeting des clec2d-klrb1-wegs
US11384344B2 (en) 2018-12-17 2022-07-12 The Broad Institute, Inc. CRISPR-associated transposase systems and methods of use thereof
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
US11149286B1 (en) 2020-08-17 2021-10-19 Mayo Foundation For Medical Education And Research Adenovirus vectors and methods for using adenovirus vectors
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017832A1 (en) * 1993-02-09 1994-08-18 The Scripps Research Institute Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US5820868A (en) 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
US6312699B1 (en) * 1994-03-28 2001-11-06 Uab Research Foundation Ligands added to adenovirus fiber
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
AU704391B2 (en) * 1994-10-28 1999-04-22 Trustees Of The University Of Pennsylvania, The Improved adenovirus and methods of use thereof
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
CZ162398A3 (cs) * 1995-11-28 1998-10-14 Gen Vec, Inc. Vektory a způsoby pro genový přenos do buněk
US6740511B1 (en) * 1999-08-27 2004-05-25 Transgene S.A. Modified adenoviral fibre and uses thereof

Also Published As

Publication number Publication date
FR2761689A1 (fr) 1998-10-09
EP0991763B1 (de) 2005-09-28
DE69831741T2 (de) 2006-07-06
CA2285565A1 (fr) 1998-10-08
ATE305513T1 (de) 2005-10-15
FR2761689B1 (fr) 1999-06-25
AU7054798A (en) 1998-10-22
US6569677B1 (en) 2003-05-27
ES2246533T3 (es) 2006-02-16
DK0991763T3 (da) 2006-02-20
EP0991763A1 (de) 2000-04-12
JP2001522236A (ja) 2001-11-13
US7256036B2 (en) 2007-08-14
WO1998044121A1 (fr) 1998-10-08
AU741728B2 (en) 2001-12-06
US20030175243A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
DE69831741D1 (de) Modifizierte adenovirale fiber und sie enthaltende adenoviren
Saharinen et al. Identification and characterization of a new latent transforming growth factor-β-binding protein, LTBP-4
BR0315275A (pt) Anticorpos que se ligam a receptor de eritropoietina
ES2169095T3 (es) Proteinas con actividad de factor viii, procedimiento para su produccion utilizando celulas modificadas por ingenieria genetica y composiciones farmaceuticas que los contienen.
NO963371L (no) Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det
IL201274A0 (en) Modified antibodies to prostate-specific membrane antigen and uses thereof
MX9706485A (es) Metodos y composiciones para terapia de genes para tratamiento de defectos en el metabolismo de lipoproteina.
NO970891L (no) Aerogelholdige komposittmaterialer, fremgangsmåte for fremstilling av disse samt deres anvendelse
MX9709549A (es) Adenovirus recombinantes, su uso para preparar aav, linea celular complementaria y composiciones farmaceuticas que los contienen.
DE60035517D1 (de) Gl50 moleküle, sowie verwendungen derselben
EP0701563A4 (de) Gen transfer zur behandlung von bindegewebe eines säugetierwirtes
NZ505063A (en) Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions
ATE256740T1 (de) Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
NZ508399A (en) Packaging cell lines for use in facilitating the development of high capacity adenoviral vectors
DE60017141D1 (de) Replikationskompetente anti-tumor vektoren
PT1007559E (pt) Celulas geneticamente modificadas que expressam as proteinas morfogeneticas do osso
WO2004007537A3 (en) Modified adenoviral fiber with ablated to cellular receptors
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
FI971896A0 (fi) BMP-tyyppi II-reseptoria koodaava cDNA
DK0625157T3 (da) Blodplade-GPIIIaP1A1- og -P1A2-epitoper og fremstilling og anvendelse deraf
ZA985090B (en) CNS neuroregenerative compositions and methods of use
DK0781095T3 (da) Celler der bærer CD4 lokkeduereceptorer og beslægtede molekyler og fremgangsmåder
DE69632201D1 (de) Regulierte expression von proteinen in stabil transformierten säugetierzellen
Dauksaite et al. The second RNA-binding domain of the human splicing factor ASF/SF2 is the critical domain controlling adenovirus E1A alternative 5′-splice site selection
FI950883A (fi) BAPP-C100-reseptorin kloonaus ja ilmentäminen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: TRANSGENE S.A., STRASSBURG/STRASBOURG, FR

8339 Ceased/non-payment of the annual fee